Antidepressant-induced bruxism: need for buspirone?

Ranjan, Sanjeev; Chandra, Prabha S.; Prabhu, Santosh

doi:10.1017/s1461145705005985

Cited by 22 publications

(11 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The research and medical records in our study did not allow us to determine the reasons for patients not undergoing a research biopsy. However, other investigators have also noted the low rate of biopsies that are actually performed when offered on a voluntary basis, with reasons that include: (a) patient-related factors, that is, hesitancy because of weighing the associated risk in the absence of direct benefit and the time commitment [16]; (b) physician-related factors, that is, physicians having a lower acceptability for risk and who are hesitant because of any additional time that might be incurred before obtaining informed consent [17]; and (c) logistical factors, such as lack of funding.…”

Section: Discussionmentioning

confidence: 99%

Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience

et al. 2011

View full text Add to dashboard Cite

Background. Research biopsies are crucial for exploring the impact of novel agents on putative targets. The current study assesses the safety and success rate associated with performing such biopsies.Methods. We reviewed the medical records of 155 consecutive patients who had one or more research biopsies as part of a phase I trial from September 2004 to October 2009.Results. Of 281 research biopsies performed, 118 were paired before and after treatment biopsies (total ‫؍‬ 236 biopsies). The most common sites of biopsy were superficial lymph node (19.9%), followed by liver (16.4%), and then soft tissue (15.7%). Ultrasound-guided biopsies were the most frequent type (53.7%). Among 142 patients who consented for mandatory biopsy, 86.6% had the biopsy performed, compared with 4.4% of 911 patients offered a

show abstract

Section: Discussionmentioning

confidence: 99%

Outcomes of Research Biopsies in Phase I Clinical Trials: The MD Anderson Cancer Center Experience

et al. 2011

View full text Add to dashboard Cite

show abstract

“…Two similar cases were successfully managed with dosage manipulation by Ranjan et al. (141). These authors argued that such is a better approach than using buspirone as an antidote.…”

Section: Pharmacological Approachesmentioning

confidence: 98%

“…Bostwick and Jaffee (140) described four cases of sertraline-induced bruxism, which were successfully treated with the serotonin 1A receptor agonist buspirone. Two similar cases were successfully managed with dosage manipulation by Ranjan et al (141). These authors argued that such is a better approach than using buspirone as an antidote.…”

Section: Pharmacological Approachesmentioning

confidence: 99%

Principles for the management of bruxism*

Lobbezoo

Zaag

Selms

et al. 2008

J of Oral Rehabilitation

237

202

View full text Add to dashboard Cite

Summary The management of bruxism has been the subject of a large number of studies. A PubMed search, using relevant MeSH terms, yielded a total of 177 papers that were published over the past 40 years. Of these papers, 135 were used for the present review. Apparently, research into bruxism management is sensitive to fashion. Interest in studying the role of occlusal interventions and oral splints in the treatment of bruxism remained more or less constant over the years: between 1966 and 2007, approximately 40–60% of the papers dealt with this subject. The percentage of papers that dealt with behavioural approaches, on the other hand, declined from >60% in the first 2 decades (1966–1986) to only slightly >10% in the most recent decade (1997–2007). In the latter period, >40% of the papers studied the role of various medicines in the treatment of bruxism, while in the preceding decade (1987–1996), only approximately 5% of the studies dealt with the pharmacological management of bruxism. Unfortunately, a vast majority of the 135 papers have a too low level of evidence. Only 13% of the studies used a randomized clinical trial design, and even these trials do not yet provide clinicians with strong, evidence‐based recommendations for the treatment of bruxism. Hence, there is a vast need for well‐designed studies. Clinicians should be aware of this striking paucity of evidence regarding management of bruxism.

show abstract

“…The exact neurochemical mechanisms that cause certain selective serotonin reuptake inhibitors (SSRIs) to manifest sleep bruxism is a focus of research efforts (9, 31, 33) as are those involved in the important comorbid factors of sleep regulation, endocrine systems, autonomic functions, stress/anxiety, and motor control (14, 15, 35-37). As demonstrated by the bruxism-ameliorating effects of the drugs gabapentin, tiagabine, gamma-hydroxybutyrate, diazepam, and lorazepam, the major neurotransmitter γ-aminobutyric acid (GABA) is suggested to play a critical role in bruxism (9).…”

Section: Introductionmentioning

confidence: 99%